Seres Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.41
- 52-Week Range
- $1.30 – $29.98
- Market Cap
- $14.68M
- P/E (TTM)
- —
- EPS (TTM)
- -5.01
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.68
- PEG Ratio
- —
- Return on Equity
- -144.35%
- Return on Assets
- -39.52%
- Gross Margin
- 0.00%
- Operating Margin
- -3115.15%
- Profit Margin
- 0.00%
- Current Ratio
- 1.65
- Debt/Equity
- 1.67
- Total Debt
- $35.77M
- Free Cash Flow
- $-38.83M
- Revenue Growth
- 68.90%
- Earnings Growth
- —
- Enterprise Value
- $32.92M
Market Snapshot
About
Seres Therapeutics, Inc. is a microbiome therapeutics company developing bacterial consortia treatments for diseases including C. difficile infection and ulcerative colitis.